Buparlisib

Renal Cell Carcinoma

Toni Choueiri, MDSmall moleculePhase 1Dormant

CC

40/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 32/ 100
Competitive Position: 65/ 100

Competitive context

145 Active assets in the Renal Cell Carcinoma cohort.

Asset / Sponsor	Phase	Rating
Alpha-Interferon Fuzhou General Hospital	Phase 3	BB
Nivolumab Fred Hutchinson Cancer Center	Phase 4	BB
su011248 Peking University Cancer Hospital & Institute	Phase 4	BB
Everolimus Merck Sharp & Dohme LLC	Phase 4	BB
Axitinib SWOG Cancer Research Network	Phase 4	BB

View all 50 →

Same molecule, other indications

Buparlisib is also rated in:

breast cancerDormant

B

Indicative ·

58 / 100

glioblastomaDormant

CCC

Indicative ·

54 / 100

Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular LymphomaDormant

CCC

Indicative ·

54 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.